Rotterdam and Leiden, the Netherlands, November 23, 2022 – Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of novel second generation TCR-T therapies against solid tumors, and NecstGen B.V., The Netherlands Center for the Clinical Advancement of Stem Cells and Gene Therapy, today announced a partnership to advance Pan Cancer T’s innovative therapies into the clinic. Under the agreement, NecstGen will provide process and analytical development capabilities. [Read more…]
Steakholder Foods® Successfully Produced Porcine Fat Cells Differentiated from iPSC for Cultivated Pork Products
This will enhance the company’s ability to produce high-quality structured pork products at scale.
REHOVOT, Israel, Nov. 10, 2022 — Steakholder Foods Ltd. (NASDAQ: STKH), (formerly MeaTech 3D: MITC), an international deep-tech food company at the forefront of the cultured meat industry, today announced that it has successfully differentiated porcine fat cells from its induced pluripotent stem cell line. [Read more…]
Novel Hydrogel System Eliminates Need For Subculture In Cell Culture Process While Retaining Key Cell Features, Reducing Number of Cells In Senescence, and Increasing Production of Therapeutic By-Products
November 16, 2022, Olathe, KS – Ronawk, the new biotech and biofabrication company powered by the Bio-Block™ platform, today shared highlights of new data published in the October issue of Regenerative Medicine. The article entitled “Novel Hydrogel System Eliminates and Improves Retainment of Non-Senescent Mesenchymal Stem Cell Populations” demonstrates the significant impact of Ronawk’s hydrogel Bio-Block™ system on the cell culture process and the ability to remove the need for subculture from the process. [Read more…]
Brexogen’s Exosome Therapy for Atopic Dermatitis, ‘BRE-AD01’ Accepted for Phase 1 Clinical Trials by US FDA
First entry to clinical trial of exosome for atopic dermatitis and the first exosome-based therapeutics in US clinical trial among Korean companies
SEOUL, South Korea I November 2, 2022 – The US FDA granted the initiation of the phase 1 clinical trial of ‘BRE-AD01’, an exosome- based therapy for atopic dermatitis. ‘BRE-AD01’ is being developed by Brexogen with its own exosome-platform technology. It is the first phase 1 clinical trial of therapeutic exosome for atopic dermatitis in major countries. This IND clearance is very meaningful in that patients with atopic dermatitis can benefit from receiving better treatment with ‘BRE-AD01’, which is armed with multiple mode of action. [Read more…]
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
SAN DIEGO, California, Nov. 01, 2022 – Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced it has entered into a sponsored research agreement with Michael Andreeff, M.D., Ph.D., Professor of Leukemia at The MD Anderson Cancer Center (“MD Anderson”). [Read more…]
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 97
- Next Page »